DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of information between the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction.
EditForce develops drugs and seeds by using nucleic acid (DNA/RNA) manipulation technologies.
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
PePerseus Proteomics is a drug discovery biotechnology venture that uses advanced antibody technology to pursue superior antibody production technology and create new medicines powerfully for people around the world who are waiting for better medical care .
AbolerIS Pharma has a novel and distinct therapeutic approach that induces immune tolerance and preserves useful immune responses in inflammatory, autoimmune, and degenerative diseases, allowing researchers to concentrate on the development of novel drugs in areas of unmet medical need.
J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.
EditForce develops drugs and seeds by using nucleic acid (DNA/RNA) manipulation technologies.
Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million dies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. Acticor Biotech was founded in November 2013 and is headquartered in Paris, France.
Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million dies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. Acticor Biotech was founded in November 2013 and is headquartered in Paris, France.
Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination. Sequana Medical’s first product, the Alfapump System, is an innovative solution for the management of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites. Sequana Medical was founded in 2006 and is based in Zurich, Switzerland.
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.
Synergia Medical aims at developing and commercializing next generation neurostimulation devices. It relies on a seasoned management team with extensive experience in developing implantable neurostimulators. In only three years time, the company became ISO13485 certified, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm and developed its first version of the NAOS platform. Supported by private investors and public research grants, the company has quickly grown to a team of thirteen highly skilled multidisciplinary professionals.
Dim3 develops and markets innovative clinical expert platforms and medical devices. Our solutions speed up medical decisions, enhance the life of patients and reduce healthcare costs. Now on the market, DIM3 first platform focuses on the fight against disease-related malnutrition. This is a major but silent threat that costs lives and an estimated 170 billions euros/year for Europe only.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.